Latest news with #AlkemLaboratoriesLtd.
Business Insider
2 days ago
- Business
- Business Insider
Alkem Laboratories Ltd. (ALKEM) Receives a Buy from Nomura
Nomura analyst Saion Mukherjee maintained a Buy rating on Alkem Laboratories Ltd. (ALKEM – Research Report) yesterday and set a price target of INR5,430.00. The company's shares closed last Friday at INR5,098.50. Confident Investing Starts Here: Mukherjee covers the Healthcare sector, focusing on stocks such as Alkem Laboratories Ltd., Cipla Ltd, and Fortis Healthcare Ltd.. According to TipRanks, Mukherjee has an average return of 12.5% and a 35.71% success rate on recommended stocks. In addition to Nomura, Alkem Laboratories Ltd. also received a Buy from ICICI Securities's Abdulkader Puranwala in a report issued on May 30. However, on the same day, J.P. Morgan maintained a Hold rating on Alkem Laboratories Ltd. (NSE: ALKEM). The company has a one-year high of INR6,440.00 and a one-year low of INR4,409.90. Currently, Alkem Laboratories Ltd. has an average volume of 2,117.
Business Insider
2 days ago
- Business
- Business Insider
Jefferies Sticks to Their Sell Rating for Alkem Laboratories Ltd. (ALKEM)
Jefferies analyst Alok Dalal maintained a Sell rating on Alkem Laboratories Ltd. (ALKEM – Research Report) on May 30 and set a price target of INR4,460.00. The company's shares closed last Friday at INR5,098.50. Confident Investing Starts Here: According to TipRanks, Dalal is a 2-star analyst with an average return of 2.0% and a 50.00% success rate. Dalal covers the Healthcare sector, focusing on stocks such as Ajanta Pharma Limited, Alkem Laboratories Ltd., and Cipla Ltd. Currently, the analyst consensus on Alkem Laboratories Ltd. is a Moderate Sell with an average price target of INR4,947.50. Based on Alkem Laboratories Ltd.'s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of INR30.32 billion and a net profit of INR5.45 billion. In comparison, last year the company earned a revenue of INR29.68 billion and had a net profit of INR2.87 billion
Time of India
30-04-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 0.93% in a weak market
NEW DELHI: The Nifty Pharma index traded positive around 10:45AM(IST)on Wednesday in a weak market. Alkem Laboratories Ltd.(up 2.32 per cent), Ipca Laboratories Ltd.(up 2.07 per cent), Lupin Ltd.(up 1.81 per cent), J B Chemicals & Pharmaceuticals Ltd.(up 1.35 per cent) and Granules India Ltd.(up 1.35 per cent) were among the top gainers. Natco Pharma Ltd.(down 1.86 per cent), Laurus Labs Ltd.(down 0.98 per cent), Abbott India Ltd.(down 0.85 per cent), Divi's Laboratories Ltd.(down 0.31 per cent) and Ajanta Pharma Ltd.(down 0.08 per cent) were the top losers on the index. The Nifty Pharma index was up 0.93 per cent at 21879.3 at the time of writing this report. Benchmark NSE Nifty50 index was down 11.46 points at 24324.5, while the BSE Sensex was down 56.93 points at 80231.45. Live Events Among the 50 stocks in the Nifty index, 28 were trading in the green, while 22 were in the red. Shares of Vodafone Idea, Vishal Mega Mart, Suzlon Energy, YES Bank and Reliance Power were among the most traded shares on the NSE. Shares of Kilitch Drug, Chambal Fertilisers, Mangalore Chem, Mazagon Dock Ship and Max Financial hit their fresh 52-week highs in today's trade, while Keerti Knowledge, GI Engineering, AGS Transact Tech, Gujarat Lease and Gensol Engg hit fresh 52-week lows in trade.
Time of India
23-04-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 1.4%
NEW DELHI: The Nifty Pharma index closed on a positive note on Wednesday. Shares of Aurobindo Pharma Ltd.(up 4.98 per cent), Alkem Laboratories Ltd.(up 4.38 per cent), Torrent Pharmaceuticals Ltd.(up 2.65 per cent), Sun Pharmaceutical Industries Ltd.(up 2.37 per cent) and Lupin Ltd.(up 2.1 per cent) ended the day as top gainers in the pack. On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 4.26 per cent), Abbott India Ltd.(down 1.76 per cent), Mankind Pharma Ltd.(down 1.32 per cent) and Laurus Labs Ltd.(down 0.16 per cent) finished as the top losers of the day. The Nifty Pharma index closed 1.4 per cent up at 21738.95. Benchmark NSE Nifty50 index ended up 161.71 points at 24328.95, while the BSE Sensex stood up 520.9 points at 80116.49. Live Events Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. Shares of Vodafone Idea, Suzlon Energy, YES Bank, IDFC First Bank and Ola Electric Mobilit were among the most traded shares on the NSE. Shares of Country Condos, Choice Intnl, Rama Phosphates, Cura Tech and Paradeep Phosphates hit their fresh 52-week highs in today's trade, while AGS Transact Tech, Gensol Engg, Dhanvarsha Finvest, Punjab Alkalies and BDR Buildcon hit their fresh 52-week lows.
Yahoo
29-01-2025
- Business
- Yahoo
Beta Lactam and Beta Lactamase Inhibitors Market to grow by USD 8.4 Billion (2025-2029), driven by novel drug development, AI-powered market evolution
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global beta lactam and beta lactamase inhibitors market size is estimated to grow by USD 8.4 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of 4.7% during the forecast period. Rising focus on novel drug development is driving market growth, with a trend towards technological advancements in antibiotic discovery. However, emergence of carbapenem-resistant enterobacteriaceae (cre) poses a challenge. Key market players include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi SA, Spero Therapeutics Inc., Taj Pharmaceutical Ltd., and Zeelab Laboratories Ltd.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Beta Lactam And Beta Lactamase Inhibitors Market Scope Report Coverage Details Base year 2024 Historic period 2019 - 2023 Forecast period 2025-2029 Growth momentum & CAGR Accelerate at a CAGR of 4.7% Market growth 2025-2029 USD 8400.9 million Market structure Fragmented YoY growth 2022-2023 (%) 4.4 Regional analysis North America, Europe, Asia, and Rest of World (ROW) Performing market contribution North America at 39% Key countries US, China, Germany, India, and UK Key companies profiled Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Lupin Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sandoz Group AG, Sanofi SA, Spero Therapeutics Inc., Taj Pharmaceutical Ltd., and Zeelab Laboratories Ltd. Market Driver The Beta Lactam and Beta Lactamase Inhibitors market is witnessing significant growth due to the increasing prevalence of infectious diseases caused by antibiotic-resistant microorganisms. Penicillin, Cephalosporin, Carbapenem, Monobactam are key antibacterial agents in this market. Combination therapies with Beta Lactamase Inhibitors are trending, especially in Urinary Tract Infections, Respiratory Infections, and Skin Infections. New molecules and oral formulations are in clinical trials to cater to the elderly population and chronic diseases. The drug class is administered through various routes, including Intravenous and oral, for conditions like Nosocomial Pneumonia, Hospital-acquired pneumonia, Ventilator-associated pneumonia, and Blood Stream Infections. Amalgamation traits of Beta Lactam and Beta Lactamase Inhibitors offer effective solutions to combat antibiotic resistance. Creative Diagnostics is a leading supplier of Beta Lactamase Inhibitors for research and diagnostic applications. Advancements in antibiotic discovery employ high-throughput screening (HTS) techniques to identify potential beta lactam antibiotics and inhibitors. HTS allows for the rapid testing of large chemical compound libraries, accelerating the discovery process and leading to the identification of novel, more effective beta lactamase inhibitors. Computational modeling, including molecular docking and virtual screening, further enhances this process by predicting binding interactions between beta-lactam antibiotics, inhibitors, and bacterial targets, ultimately contributing to the development of new antibiotics to combat antimicrobial resistance and infectious diseases. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The Beta Lactam and Beta Lactamase Inhibitors market encompasses antibacterial agents used to combat various microorganisms causing Urinary Tract Infections, Respiratory Infections, Skin Infections, Nosocomial Pneumonia, and Blood Stream Infections. Penicillin, Cephalosporin, Carbapenem, and Monobactam are key drug classes. However, antibiotic resistance poses a significant challenge. Creating new molecules and combination therapies, such as Cephalosporin with Beta Lactamase Inhibitors, is crucial. Route of administration varies from Intravenous to Oral. The prevalence of infectious diseases, particularly in the elderly population, increases the market demand. Amalgamating traits of both antibiotics and inhibitors can lead to effective treatments for chronic diseases and complex infections like Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, and more. Clinical trials are ongoing to ensure safety and efficacy. Carbapenem-resistant Enterobacteriaceae (CRE) strains pose significant challenges for healthcare providers due to their resistance to carbapenem antibiotics, which are commonly used for treating serious bacterial infections. The emergence of CREs limits effective treatment options, leading to increased morbidity and mortality rates for patients. Infections caused by CREs are often associated with prolonged hospitalization and higher healthcare costs. These bacteria are commonly found in healthcare settings, including hospitals, long-term care facilities, and intensive care units, making infection control efforts crucial. Nosocomial transmission of CREs among patients can lead to outbreaks and healthcare-associated infections, further complicating treatment and increasing the risk of dissemination within healthcare facilities. Effective strategies for managing CRE infections include the use of beta-lactam/beta-lactamase inhibitor combinations and other alternative antibiotics. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This beta lactam and beta lactamase inhibitors market report extensively covers market segmentation by Route Of Administration 1.1 Oral 1.2 Intravenous 1.3 Others Drug Class 2.1 Cephalosporins 2.2 Penicillins 2.3 Carbapenem 2.4 Monobactum 2.5 Combination Geography 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Oral- Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Beta Lactam and Beta Lactamase Inhibitors market refers to a class of antibacterial agents used to treat various bacterial infections. These agents work by inhibiting the action of beta-lactamases, enzymes produced by microorganisms that can break down antibiotics like Penicillin, Cephalosporin, Carbapenem, Monobactam, and others. New molecules and combination therapies are being developed to combat the growing resistance to beta-lactam antibiotics. Clinical trials are ongoing to evaluate the safety and efficacy of these new drugs, particularly in the treatment of chronic diseases and in the elderly population. Beta-lactam and beta-lactamase inhibitors are available in various forms, including oral preparations, and are used to treat a wide range of bacterial infections. Market Research Overview Beta lactam and beta lactamase inhibitors are a class of antibacterial agents used to treat various bacterial infections. These agents work by inhibiting the action of beta-lactamases, enzymes produced by microorganisms that can break down antibiotics like penicillin, cephalosporin, carbapenem, monobactam, and others. The use of beta lactam and beta lactamase inhibitors is essential in the treatment of urinary tract infections, respiratory infections, skin infections, nosocomial pneumonia, bloodstream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia. With the increasing prevalence of infectious diseases and the emergence of antibiotic resistance, the development of new molecules and combination therapies is a priority. The drug class is available in various routes of administration, including intravenous and oral forms. The elderly population and those with chronic diseases are particularly susceptible to bacterial infections and benefit from the use of these agents. The amalgamation of traits from different beta lactam antibiotics in combination therapies offers improved efficacy and reduced risk of resistance. Creative Diagnostics provides comprehensive solutions for beta lactam and beta lactamase inhibitors, including assay kits, antibodies, and services, to support research and development in this field. Table of Contents: 1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation Route Of Administration Drug Class Geography 7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. ContactsTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@ View original content to download multimedia: SOURCE Technavio Sign in to access your portfolio
